Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stem Cells--A Proliferating Ambition

This article was originally published in Start Up

Executive Summary

Stem cells have applications in organ and tissue repair, gene therapy, drug discovery, and bioartificial organs. Companies are trying to find, grow, and control human embryonic stem cells—totipotent progenitor cells that can give rise to all the tissues in the human body. Investors are intrigued by the opportunity--after all, Sandoz bought 60% of SyStemix at a big premium--but are unnerved by the early-stage of stem cell science, and the all-or-nothing races for patents.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089696

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel